new glp-1 agonists Guidelines for Type 2 Diabetes in 2025 Curious about the latest in
Description
PubMed Central , Accessed 23 Apr
GLP-1 therapies like Semaglutide have demonstrated strong efficacy and safety profiles, encouraging healthcare providers to use them as initial interventions rather than as last-resort options
( 10.1056/NEJMoa1607141) [DOI] [PubMed] [Google Scholar] 50.Bethel MA, Diaz R, Castellana N, Bhattacharya I, Gerstein HC, Lakshmanan MC
As a result, liraglutide-loaded microspheres effectively reduced fasting blood glucose (FBG) and hemoglobin A1c (HbA1c) levels while improving pancreatic and hepatic functions in db/db mice
The SURMOUNT-5 head-to-head trial directly compared Zepbound to Wegovy, with results published in The New England Journal of Medicine: The addition of GIP receptor activation unlocks approximately 6% additional fat loss compared to GLP-1-only medications, while also helping preserve muscle mass better
Ten-year follow-up in sleep AHEAD
